Key

Disease stage

Tag Description
Any stage A population with RA whose prior treatments are unclear
Biological-naïve Treatment of patients who have not received prior biological therapy, with or without prior traditional DMARDs
Dose tapering Patients who achieved remission on therapy and where the impact of tapering the dose is being assessed
Early Patients who are naive to any prior treatment for RA
Fourth-line biological Patients who have already failed to be managed by 3 prior biological therapies
Remission Patients who have achieved remission with therapy for RA
Second-line biological Patients who have already failed to be managed by 1 prior biological therapy
Third-line biological Patients who have already failed to be managed by 2 prior biological therapies
Treatment sequences Models that assess the sequence of biological therapies

Study methodology

Tag Description
Cost-benefit Study where the outcome is measured in financial terms e.g. return on investment, cost savings
Cost-effectiveness Studies where the outcome is cost per clinical outcome e.g. per patient who achieves ACR20 or who achieves disease remission
Cost-utility Studies where the outcome is cost per quality-adjusted life-year (QALY)
Systematic literature review Studies on a topic are identified from systematic searches of the literature, includes meta-analysis